

In Barcelona, it being 4 p.m. on 5 May 2014, at the Hotel Gallery located in Carrer Roselló, 249 in Barcelona, under the presidency of Mr. Josep Carreras Coll and acting as Secretary the holder of that post, Mr. Calixto Mut Terrés-Camaló, the Board of Trustees of the Josep Carreras International Leukemia Foundation met with the personal attendance of the Trustees listed below.

Present:

Mr. Josep Carreras i Coll

Prof. Evarist Feliu i Frasnado

Mr. Albert Carreras i Coll

Dr. Clarence Dean Buckner

Dr. Rainer Storb

Mr. Ramiro Giménez i Labrador.

Mr. Marcel Pascual i Forns

Mr. Arcadi Calzada i Salavedra

Dr. Joan Uriach i Marsal

Mr. Albert Carreras i Pérez,

Dr. Alvaro Urbano i Izpizua

Prof. Jordi Sierra i Gil

Also attending:

Mr. Antoni García i Prat (Administrator)

Dr. Enric Carreras i Pons (REDMO Director)

Mr. Calixto Mut i Terrés-Camaló (Secretary of the Board and legal advisor)

With the justified absence of the following who delegate their vote to the President:

Mr. Lluís Bassat i Coen

Prof. Rafael Jiménez de Parga i Cabrera

Mr. Joaquim Folch-Rusiñol

The meeting was duly convened in accordance with Articles 20 and 21 of the Foundation's Statutes with the following Agenda:

1. Reading of the minutes of the previous meetings, held on 11 April and 12 December 2013, which had been approved and signed at the close of those meetings.

2. Renewal of posts on the Board. Renewal of the Trustees Albert Carreras Coll, Clarence Dean Buckner, Ramiro Giménez Labrador, Rafael Jiménez de Parga Cabrera and removal from the board of the Trustee, the late Albert Grañena Batista.
3. Information on scientific programs and grants. Annual Report
4. Josep Carreras International Leukemia Institute. Status Report
5. Reception apartments
6. Information regarding REDMO
7. Initiatives by the President. Benefit concerts and other fund-raising activities
8. Strategic Plan update
9. Proposed closure of the financial year 2013
Annual report and accounts
 - 9.1 Responsible Declaration concerning the award of projects to the IJC
10. Proposed budget for the year 2014
11. Responsible Declaration for the sale of property
12. Activities report 2013
13. Temporary financial investments in 2013
14. Any further business

The meeting having begun, and declared validly constituted by the Chair, who greeted all those present, and after various deliberations, of which no record was requested in the Minutes, the following agreements were approved unanimously:

FIRST: Approval of the definitive version of the Minutes of the meetings of the Board of Trustees held on 11 April and 12 December 2013, which had already been approved at the close of those meetings.

SECOND: 2.1 Inform the Supervisory Body of the decease of the Trustee Dr. Albert Grañena Batista which occurred on 18 October 2013, to be documented as necessary.

2.2 The following Trustees were renewed in their posts for a period of five years: Mr. Albert Carreras Coll, of Spanish nationality, of the age of majority, married, businessman with National Identity Number 37144908-T, Mr. Clarence Dean Buckner, United States citizen, of the age of majority, married, doctor with passport number 1498120103, Mr. Ramiro Giménez Labrador, of Spanish nationality, of the age of majority, married, businessman with National Identity Number 37908212A, Mr. Rafael Jiménez de Parga Cabrera, of Spanish nationality, of the age of majority, married, lawyer with National Identity Number 02147986Q, the first three of whom,

being present at the meeting, accepted the appointment and declared themselves not to be in a situation of legal incompatibility and that their unchanged personal details were already registered at the Foundations Registry except for Mr. Clarence Dean Buckner's passport number which is new. Mr. Rafael Jimenez de Parga Cabrera, who was not present at the meeting, will accept the post in a separate document.

THIRD: Dr. Feliu reported on the scientific programs, and on the grants awarded.

Award of the International Grant (FIJC-13/EDTHOMAS) Commencing June 2014. Number of projects presented: 30 (19 USA, 7 Spain, 1 Sweden, 2 Australia, 1 Germany) **Bestowed on:** Thomas Schmitt, Ph.D. Fred Hutchinson Cancer Research Center - Seattle WA, USA. **Title of the Project:** Targeting leukemia with enhanced-affinity TCR gene therapy. **Work center:** Fred Hutchinson Cancer Research Center - Seattle WA, USA **Project Director:** Philip Greenberg, PhD. **Amount:** 50,000 euros/year (extendable for two years).

Award of the José Carreras Young Investigator Fellowship Grant (EHA-013). Number of projects presented: 28 **Bestowed on:** Dr. Luca Mazarella. **Title of the Project:** Obesity-associated FLT3 mutations in Acute Promyelocytic Leukemia: investigating a novel paradigm for the cancer promoting effect of obesity” **Work center:** European Institute of Oncology (IEO), Molecular Oncology Laboratory/State University, Milan, Italy **Project Director:** Prof. Piergiuseppe Pelicci **Amount:** 50,000 euros/year (extendable for one year).

Dr. Feliu then commented on the follow-up for grants awarded previously as described in the documents made available to the Trustees.

Dr. Feliu also provided information about the proposal to establish a new FHCRC/FIJC/ IJC grant which would run from 12 to 24 months and would be addressed to graduates in the last five years and which would bear the name of Professor Thomas.

He also provided information about the proposal to abolish the ISAB, cancel the grant and create a new three-year grant at the IJC, on condition it be financed by the German Foundation. The Board approved both proposals.

Finally, Dr. Feliu provided information about the establishment of a Presidential endowment (P/AG) at the St. Pau Campus to be paid to the IJC which will supervise its purpose and application and he summarized the scientific production achieved through previously awarded presidential grants at the St. Pau Campus (Dr. Ramón Mangués' group).

FOURTH: Dr. Feliu reported on the situation at the Josep Carreras Leukemia Research Institute.

Three years after its creation the IJC continues to grow and to carry out its activities according to plan.

At the Hospital Clínic Campus, Dr. Pablo Menéndez Buján joined the team on 1 September 2013 as ICREA Senior and Hospital Clínic Campus Research Director. The proposed contract mentions that the IJC is to provide a complement to the ICREA salary and, furthermore, undertakes to provide a start-up of 90,000 euros/year for two years (2014-2015) from the funds of the Josep Carreras Leukemia Research Institute (FIJC). The sum corresponding to the first year has already been received and in 2014 the sum corresponding to the second year will be awarded. With regard to the research team a junior leader group has been incorporated (indefinite contract) through a Miguel Servet II grant and the rest of the team, that has arrived at the University of Barcelona Hospital Clínic Campus with their own grants, will be partially financed for three years by the IJC to the total sum of 893,850 euros.

The construction and equipping of the research laboratory at the University of Barcelona Faculty of Medicine (250m²) has commenced: offices, genetics, flow cytometry, cellular and molecular biology and cell sorting. A contribution has also been made to the construction of a cryopreservation laboratory and to the refurbishing of the animal unit. In a similar vein, improvements have been made to the University of Barcelona's central facilities for the use also of IJC staff: proteomics, GMP rooms for tissue cultivation and confocal microscopy. An opening ceremony is planned to take place during the second half of 2014.

The team consists of Pablo Menéndez himself as senior researcher, a junior researcher with an indefinite contract, an associate researcher, 3 post doctorals, a lab manager and three students. They have been given access to all the IJC's core facilities and all the technological platforms as well as administrative support.

Works at the Faculty of Medicine have cost 837,466 euros and the equipment (an irradiator for experimental transplantation in mice, cellular separator, incubation chambers with CO₂, cryopreservation tank, etc.) have cost 1,741,059 euros, all of which has been funded by the FIJC (Total: 2,578,525 euros).

Work groups have been established with clinical leaders in different lines of research: Myeloma and MGUS (J. Bladé), Acute Myeloblastic Leukemia (J. Esteve), Cellular Therapy and Transplantation (HSC) (A. Urbano, E. Carreras), Pharmaceutical research for the differentiation of leukemic stem cells (RM. Risueño), infantile acute lymphoblastic leukemia, mesenchymal stem cells, malignant blood disease models in animals and Xenotransplantation of hematopoietic progenitors (P. Menéndez).

At the Catalan Institute for Oncology/Germans Trias i Pujol Campus (ICO/GTiP) Dr. Francesc Solé was contracted on 1/10/2012 as Head of the Cytogenetics Platform, main myelodysplastic syndrome (SMD) researcher and ICO/GTiP Campus Research Director.

Since October 2012 work has been undertaken at the ICO/GTiP Campus in a 100m² area of the Institute for Predictive and Personalized Cancer Medicine (IMPPC). The basic and executive

projects of phase 0 of the building work have been carried out. The administrative concession of the plot of land where the building is to be constructed has been inscribed at the Badalona Property Registry and building permission has been received. Construction work was awarded to the OHL company and on 11 April the contract was signed. Building work is due to commence on 28 April. Construction will be modular and in three phases, the intention being to avoid having the building constructed but not occupied. Phase 0, earth removal, car park and general structure of the building (approximate cost 3,196,000 euros, funded by the FIJC); phase I ground floor with services shared with other institutes (auditorium, cafeteria, library, administration, computing, microscopy and bioimage platform, cryobiology platform) and 50% of the laboratories on the 3 floors (approximate cost 6,883,350 euros) and phase II, the second half of the laboratories on the three floors, in accordance with the structural and functional needs of the IJC. It should be mentioned that, given the present situation of the construction industry in Catalonia, the estimated costs mentioned might be reduced by 20-25%, something that has in fact happened with phase 0 which was concluded for 2,100,000 euros. The building is due to open in the second quarter of 2016.

At the ICO/GTiP Campus work groups have also been established with the campus's main clinical researchers: acute lymphoblastic leukemia (JM. Ribera), lymphomas in general and HIV positive (JM. Sancho, JT. Navarro), multiple myeloma (A. Oriol), myelodysplastic syndromes (F. Solé, L. Zamora, B. Xicoy), transplant of hematopoietic precursors (C. Ferrà), infections in patients with granulocytopenia (M. Batlle), Cytogenetics of malignant blood diseases (I. Granada).

Work has commenced on the project for a **third campus (St. Pau Campus)** in the form of integrating the Josep Carreras Leukemia Research Institute with the Hospital de St. Pau Hematology Service, Hematology and Transplantation Group and the Biomedical Research Institute. This proposal had already been accepted by the Hospital de St. Pau Research Foundation management, the Delegate Committee of the FIJC, the Board of the FIJC, the Delegate Committee of the IJC and the Board of the IJC. At the St. Pau campus the proposal has been made to create the post of Research Director but the location is yet to be determined. The most suitable location might be a floor of the new research building planned for the Hospital de St. Pau. At this campus too, lines of research work have been established with the main clinical leaders: lymphoproliferative syndromes (J. Briones, C. Moreno), monoclonal gammopathies (M. Granell), lymphomas (J. Briones), acute myeloblastic leukemia (J. Sierra), myelodysplastic syndromes (S. Brunet CETLAM), hematopoietic transplantation (J. Sierra), signaling, stroma, leukemic stem cell, acute myeloid leukemia in animal models and diffuse large B-cell lymphoma (DLBCL), and preclinical trials (I. Casanovas, R. Mángues), chronic myeloproliferative neoplasms (S. Saavedra), thrombophilia and cancer (JC. Souto), early phase clinical trials platform (J. Sierra, M. Granell), cell based, anti-tumor and anti-infection immunotherapies.

At the present time there are 19 staff members at the University of Barcelona Hospital Clínic Campus and 6 at the Catalan Institute for Oncology/Germans Trias i Pujol Campus (ICO/GTiP). Additionally there are the members of staff at the three Hematology Services that are assigned to, or in the process of being assigned to, the IJC.

Notably, with regard to investment, work has commenced with the Affymetrix to carry out all the array methodologies for malignant blood diseases with a genetic origin: expression arrays, genomic arrays, comparative genomic hybridization arrays, miRNA arrays, drug metabolism array and transcriptome arrays.

The IJC Organizational Chart has been drawn up and the Institute's Web site has been completed with the following messages: one single Institute, one scientific management, three campuses with a research director at each campus, 10 lines of research each with their own main researchers and work groups, minimum administrative structure that is highly professional and very focused on the raising of resources, the strengthening of scientific patronage (banks, pharmaceutical laboratories, etc.) and, above all, the recruiting of talent and the avoidance always of the duplication of research at the Institute's various campuses. Proposals for intellectual and industrial property rights regulations have also been approved as well as a communication and collaboration plan for the raising of funds between the FIJC (a not-for-profit Private Foundation) and the IJC (Research Centers of Catalonia-CERCA Public Institute). In 2013 twenty research projects were requested to the value of 5,855,000 euros, 1,242,587.66 euros being obtained (%).

In 2013 the SUMA project report was presented on the process of integration of the Institute for Predictive and Personalized Cancer Medicine (IMPPC) into the Germans Trias i Pujol Institute on Health Sciences (IGTiP) and the IJC, in accordance with the aims of the Generalitat de Catalunya of concentrating the number of research institutes, increasing their critical mass and improving their administration. The document was signed by representatives of the three institutions: Dr. M. Perucho (IMPPC), Dr. M. Puig (IGTiP) and Dr. E. Feliu (IJC). Of the eleven research groups at the IMPPC, four (Dr. Marcus Buschbeck, Dr. Mayka Sánchez, Dr. Tania Vavouri and Dr. Fumiichiro Yamamoto), together with their teams, will henceforth form part of the IJC and will, in the future, focus their research on malignant blood diseases.

Scientific production during the course of 2013 can be considered to have been very good with 53 articles published, 60% of them in the first quartile. Furthermore, from 2011 to 2013 ten doctoral theses were presented and 12 more are being prepared.

The clinical and laboratory research groups have met regularly. There have also been regular meetings of the Internal Scientific Committee in which each campus is equally represented with five members, and which Dr. Pablo Menéndez, Dr. Francesc Solé and Dr. Jordi Sierra have joined. In 2013 the External Scientific Committee was established consisting of Prof. L. Luzzatto, of the University of Florence, Prof. R. Sackstein, of the University of Harvard, Prof. F. Lococo, of the University of Rome and Prof. A. Orfao, of the University of Salamanca.

The following collaboration agreements have been signed: ICREA-IJC (2013), FIJC-IJC-UB (2013), IGTiP-IJC (2013) and on 6 May 2014 the following agreements are due to be signed: ICO-IJC and IGTiP-IMPCC-IJC (Scientific Collaboration Agreement).

On 17 December the IJC underwent CERCA evaluation. The report is favorable. The four major recommendations made were the following:

1. The need to incorporate a Scientific Director.
2. To draw up a Strategic Plan for the next four years (2014-2018).
3. Sign the collaboration agreements and accords with the hospital institutions, research institutes and universities.
4. Strengthen joint work with the External Scientific Committee.

A document proposing the regulation of intellectual and industrial property rights has also been drawn up and was approved by the Delegate Committee on 5 December 2013.

Finally, an Action Plan has been drawn up for 2014 covering five areas. **a) Scientific:** Implement the Strategic Research Plan (PEI) 2014-2018, increase competitive funding, develop patents and spin offs, increase scientific production (articles, citations, % Q1), promote the presentation of doctoral theses, develop a quality management system and register for publications (interconnections) and establish a system for collecting biological samples from patients with malignant blood diseases. **b) Staffing:** Work to create the Scientific Management at the St. Pau Campus and consolidate the Talent Recruitment Plan in relation to the Strategic Research Plan (PEI) 2014-2018. **c) Administration:** Create an organizational chart for the IJC to determine the scientific activity, staff resources, the costs and solvency of the Center and adapt the support processes for research and administration to the European quality management system (EFQM) in order to achieve accreditation; persuade the Generalitat to provide an additional €300,000 which are needed to balance the 2014 budget, otherwise reserves will have to be used to balance the books at the end of the financial year. **d) Structural:** Expand the Hematology-oncology Research Unit at the University of Barcelona Hospital Clínic Campus, create the Clinical Research Support Unit at the ICO/GTiP Campus, build phase 0 of the IJC building at the ICO/GTiP Campus, draw up the Basic, Executive and Architectural projects for phase 1 of the IJC building at the ICO/GTiP and determine the physical location of the St. Pau Campus. **e) Institutional:** Establish framework agreements and collaboration agreements with FIJC, FCRB, IDIBAPS, HCB, ICO, IIB St. Pau, H. St. Pau, UAB and draft an IJC sponsorship and patronage manual to homologate relations with the pharmaceutical industry and civil society in general.

FIFTH: The Administrator, Mr. Antoni García Prat, described the current situation with regard to the reception apartments for patients and their families who might need them as well as indicating their level of occupation, on average 65%, the highest level being 100% (Carrer Mare de Deu de Bellvitge) and the lowest being 40% (Carrer Villarroel). In total 33 patients have

benefited from these apartments along with 70 family members with a total of 1,440 days' occupation. The President once again expressed his satisfaction at this complementary aspect of the Foundation's work.

SIXTH: Dr. Carreras informed the Board about REDMO's (Spanish Register of Bone Marrow Donors) activities during 2013, placing special emphasis on the total number of donors who have joined (25,828), meaning that by the end of the year there was a total of 132,335 categorized and available donors, an annual growth of 24% for REDMO.

He also provided information concerning the number of units available from Spanish umbilical cord blood banks, 58,848 at the end of 2013 (an increase of 6%), the quality of the cells having improved a great deal in general although only 3,770 units were added during 2013, that is to say, 4% more than the previous year.

A total of 859 searches began in 2013 (11% more) and donors were found for 982 patients.

The average length of a search in 2013 was 41 days.

There were 483 hematopoietic transplantations in 2013 (6% more), 81 bone marrow transplantation, 301 for peripheral blood and 101 for umbilical cord blood.

SEVENTH: The Board was informed by the Administrator, Mr. Antoni Garcia Prat, about the President's activities.

He also gave details of the progress being made to attract and manage members. The number of members has grown by 12,873. The Autonomous Communities in which the number of members has grown most are Madrid, Catalonia, Galicia and the Balearic islands. Mr. Ramiro Gimenez made reference to the disparity in growth and presence existing between the various Autonomous Communities and Mr. García Prat commented on how this depends to a great extent on whether there is, or is not, an enthusiastic, dynamic person in each Community capable of taking the initiative. Be that as it may, the campaigns that are underway are, in general, producing satisfactory results.

EIGHTH: The administrator, Mr. Garcia Prat, provided information about updating the Strategic Plan 2012 -2017.

NINTH: The proposed budget closure for the 2013 financial year was approved as was the Annual Accounts Report as detailed in the Appendices presented by the Administrator.

PROFIT AND LOSS ACCOUNT FOR ACTIVITIES
during the financial year ending on 31 December 2013
(In Euros)

2013

INCOMES AND DONATIONS

Donations

Non-conditional	4.718.014,20	3.6
Conditioned to Foundation activity	232.345,23	2
Sponsorship Incomes	173.709,30	
Grants, donations and legates allocated to year result	795.641,63	9
	5.919.710,36	4.8

REDMO research income	15.176.144,44	15.8
------------------------------	----------------------	-------------

Extraordinary Incomes

Financial Incomes	759.559,61	9
Other Incomes	32.164,03	
Extraordinary incomes	37.983,27	
Positive exchange differences	2.586,09	
	832.293,00	1.0

	<u>21.928.147,80</u>	<u>21.7</u>
--	-----------------------------	--------------------

APPLICATIONS AND EXPENSES

Applications of Foundation activities

Research programmes and grants	1.986.020,37	1.6
Sheltered accommodation	728.331,51	4
Program F.Farreras Valenti	26.821,21	
Donor Registry (REDMO)	16.774.846,19	16.5
	19.516.019,28	18.6

Non-itemised Expenses

Personnel expenses	321.396,01	3
Allocations to depreciation	20.605,26	
Other fixed expenses	933.482,11	4
	1.275.483,38	8

Other Expenses

Financial expenses	0,00	
Negative exchange differences	890,66	
Looses per impairment and othes	189.574,56	1
Extraordinary expenses	83.322,66	
	273.787,88	2

	<u>21.065.290,54</u>	<u>19.7</u>
--	-----------------------------	--------------------

Pre-Company Tax Surplus (Losses)

	862.857,26	2.0
--	-------------------	------------

BALANCE SHEET
during the financial year ending on 31 December 2013

(In Euros)

	<u>2013</u>	<u>2012</u>
ASSETS		
NON CURRENT ASSETS	23.118.635,92	5.754.943,94
Intangible fixed assets	167.236,38	170.389,10
Tangible fixed assets	1.740.089,65	1.806.212,85
Long-term sureties	352.394,67	360.753,40
Financial Assets	20.858.915,22	3.417.588,59
CURRENT ASSETS	21.921.886,24	36.192.302,48
Non Current Assets hold to sale	986.562,82	965.589,42
Account receivables	6.873.981,33	7.584.826,24
Short term financial investments	11.434.492,57	24.084.233,09
Treasury	10.190,40	10.190,40
Tota Current Assets	2.616.659,12	3.547.463,33
<u>TOTAL ASSETS</u>	<u>45.040.522,16</u>	<u>41.947.246,42</u>
EQUITY AND LIABILITIES		
EQUITY	31.899.141,18	30.861.154,51
Foundation Fonds	27.451.321,27	27.018.941,12
Foundation Fonds	18.004.685,31	18.004.685,31
Surpluses (looses) pending application	8.583.778,70	6.981.101,56
Surpluses (looses) from the financial year	862.857,26	2.033.154,25
Value adjustments	330.404,54	167.217,60
Grants, donations and legates received	4.117.415,37	3.674.995,79
NON CURRENT LIABILITIES	6.076.679,77	5.000.600,00
Long term provisions	0,00	0,00
Long term account payables	6.076.679,77	5.000.600,00
CURRENT LIABILITITES	7.064.701,21	6.085.491,91
Short term account payables	7.064.701,21	6.085.491,91
Foundation activity beneficiaries	120.314,21	30.314,21
Accounts payables	2.154.479,05	2.242.190,70
Staff payable	4.235.868,30	3.694.964,71
Tax Authorities	44.395,01	44.992,06
Prepayment adjustments	80.954,75	73.030,23
Ajust per periodificació	428.689,89	0,00
<u>TOTAL EQUITY AND LIABILITIES</u>	<u>45.040.522,16</u>	<u>41.947.246,42</u>

DESE: S'aprova el pressupost per al exercici 2014 presentat pel Sr. Gerent, que consta de les següents partides:

PRESSUPOST

pressupost 2014

INGRESSOS I DONACIONS

Donacions	4.445.640,09
No condicionades	4.410.950,39
Condicionades a l'activitat fundacional	34.689,70
Altres	0,00
Activitats Programades	21.675.177,25
Registre de Medul·la Òssia	16.250.000,00
Centre Recerca	5.000.000,00
Ingressos Financers	400.000,00
D'Altres Ingressos	25.177,25
TOTAL INGRESSOS I DONACIONS	26.120.817,34

APLICACIONS I DESPESES

Aplicacions de l'activitat fundacional	22.499.024,95
Programes i Beques per a la recerca	300.000,00
Pisos d' acollida	99.419,95
Registre de Donants (Despeses Directes)	16.861.600,00
Ajuts i Assignacions	0,00
Programa Docent Farreras Valentí	13.005,00
Centre Recerca	5.225.000,00
Despeses d'Estructura no Desagregable	3.546.792,39
Despeses de Personal	464.000,00
Dotacions de l'exercici a amortitzacions	55.000,00
D'altres Despeses d'estructura	3.027.792,39
Despeses relacionades amb ingressos extraordinaris	0,00
D'altres Despeses	0,00
Dif.canvi	0,00
TOTAL APLICACIONS I DESPESES	26.045.817,34

Excedent (Dèficit) abans de l'Impost sobre Societats **75.000,00**

Impost sobre Societats 0,00
 Aplicacions reserves 0,00

Excedent (Dèficit) de l'Exercici **75.000,00**

ELEVENTH: It was also agreed to adopt the responsible declarations for the sale of a property received in legacy to fund various expenses of the Josep Carreras Leukemia Research Institute and to inform the Supervisory Body:

11.1. To proceed with the sale of the property located in Rubi, Carrer Font de la Via, 19 for the sum of ONE HUNDRED AND FIFTY THOUSAND EUROS (€150,000) in line with market and economic criteria. Given the location of the property it can not be used for any of the foundational aims and, being in a deficient condition, its maintenance implies continuing expense while its lack of use leads to further decay and a consequent reduction in value. Furthermore, given the attempts by squatters to occupy the property over recent months, many things have been damaged and this has meant that a continuous security service has been required. With the sale of the property the Foundation will have liquidity to comply with its undertakings with the Generalitat de Catalunya. The Foundation will be able to comply with its obligations undertaken in the collaboration agreement with the Generalitat de Catalunya for the creation and start up of the Josep Carreras Leukemia Research Institute Public Foundation, for the promotion, design and construction of the building that will house the research center at the Germans Trias i Pujol Campus and for the acquisition of equipment for it.

11.2.- To ratify the sale of the property located in Alfàs del Pi (Alicante) Calle Manuel de Falla,1, carried out for reasons of urgency on 2 February 2012 for a price of ONE HUNDRED AND TWENTY THOUSAND EUROS (€120,000) in line with market and economic criteria. Given the location of the property it can not be used for any of the foundational aims and, being in a deficient condition, its maintenance implies continuing expense while its lack of use leads to further decay and a consequent reduction in value. With the sale of the property the Foundation will have liquidity to comply with its undertakings with the Generalitat de Catalunya. The Foundation will be able to comply with its obligations undertaken in the collaboration agreement with the Generalitat de Catalunya for the creation and start up of the Josep Carreras Leukemia Research Institute Public Foundation, for the promotion, design and construction of the building that will house the research center.

11.3 In compliance with and in implementation of the agreements subscribed by the Foundation within the framework of the creation of the Josep Carreras Leukemia Research Institute Public Foundation it was agreed to make a donation towards the architectural and executive projects for the building that will house the Institute on the ICO-Germans Trias i Pujol Campus in Badalona commissioned by the Foundation and drawn up by the architect Mr. Eduardo Talon in order that the Institute may proceed with the public call for tender for its construction. Both

payments, for sums of €231,975.00 and €197,610.00 respectively, were made from funds generated by the sale of properties received in legacy, donations from third parties intended to help us with the establishment of the Institute and reserve funds generated through operating surpluses not transferred to the foundational fund. No product was obtained from this outlay other than compliance with prior agreements and obligations undertaken within the framework of the creation of the Josep Carreras Leukemia Research Institute since it was a free donation towards the architectural and executive projects defrayed by the Foundation. It contributes significantly to the creation of the Josep Carreras Leukemia Research Institute as was agreed at the appropriate time.

TWELTH: The proposed 2013 Foundation Activities Report was approved as detailed in the Appendix presented by the Administrator.

THIRTEENTH: The Treasurer and the Administrator informed the Board about compliance with the instructions in the Bank of Spain's Code of Conduct concerning temporary investments by not-for-profit organizations. The Administrator, Mr. Garcia Prat, drew attention to the negative evolution of rates of interest on bank deposits and other guaranteed financial instruments, the only assets in which the Foundation invests with the exception of portfolios received as inheritance or in legacy, including usufruct, maintained unaltered from the condition in which it was received.

FOURTEENTH: There being no further business to record in the Minutes, it being 8 p.m. the meeting was concluded and these Minutes approved by all those in attendance and signed by the Secretary and the President as proof of their approval.